Blood cancers

Checkpoint inhibitors may cause irAE in many lymphoma patients

Immune checkpoint inhibitors (ICI) that are used to treat lymphoma have been linked with a high rate of immune related adverse events (irAE) in cancer patients. Smokers and patients of older age were found to be at particular risk, suggests an analysis led by Dr Margaret M. Byrne, a haematologist and oncologist at Tufts Medical ...

Already a member?

Login to keep reading.

© 2021 the limbic